AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37673642 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral focused ultrasound subthalamotomy (FUS-STN)
Number of subjects: 12
Study 37673858 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet maintenance therapy (olaparib, pembrolizumab, bevacizumab)
Number of subjects: 44
Study 37674129 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-in-arm gait training (intervention group)
Number of subjects: 66
Study 37674129 — intervention group
Group type: COMPARATOR
Intervention: Side-by-side walking without contact (control group)
Number of subjects: 66
Study 37674135 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-item Whiteley Index (WI-14)
Number of subjects: 423
Study 37674135 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Attitude Scale (IAS)
Number of subjects: 423
Study 37674135 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-item Health Anxiety Inventory (HAI-64)
Number of subjects: 423
Study 37674135 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-item Health Anxiety Inventory (HAI-18)
Number of subjects: 423
Study 37674135 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint factor analysis of WI-14, IAS, HAI-64, HAI-18, and HAI-14
Number of subjects: 423
Study 37674161 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of caregiver mastery over time
Number of subjects: 154
Study 37674184 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation virtual reality intervention
Number of subjects: 0
Study 37674184 — intervention group
Group type: COMPARATOR
Intervention: Standard care offered by public funded maternity services
Number of subjects: 0
Study 37674205 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-education exercises involving preactivation of the abdominal transverse muscle
Number of subjects: 35
Study 37674205 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 35
Study 37674214 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible outpatient treatment model
Number of subjects: 22
Study 37674358 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen, human-tvmh (6.6 mg/kg administered every 2-5 days for 48 weeks and every 1-7 days for up to 124 weeks)
Number of subjects: 15
Study 37674358 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen, human-tvmh
Number of subjects: 15
Study 37674384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone)
Number of subjects: 0
Study 37674384 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0
Study 37674384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pola-R-CHP
Number of subjects: 0
Study 37674551 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 120
Study 37674551 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 120
Study 37674551 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 120
Study 37674656 — intervention group
Group type: EXPERIMENTAL
Intervention: Online OurRelationship program with full-coach support
Number of subjects: 740
Study 37674656 — intervention group
Group type: EXPERIMENTAL
Intervention: Online OurRelationship program with varying levels of coach support
Number of subjects: 740
Study 37674656 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 740
Study 37674711 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min daily bright blue-green light (12,000 lux)
Number of subjects: 30
Study 37674711 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (5 lux)
Number of subjects: 30
Study 37674711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (bright blue-green light and dim red light)
Number of subjects: 30
Study 37674733 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized telephone counseling
Number of subjects: 577
Study 37674733 — intervention group
Group type: COMPARATOR
Intervention: State Quitline referral
Number of subjects: 577
Study 37674777 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (spinning) for 12 weeks, three times weekly
Number of subjects: 12
Study 37674777 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12
Study 37674806 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (an ARNi)
Number of subjects: 0
Study 37674806 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (an ARB)
Number of subjects: 0
Study 37674871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 103
Study 37674889 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-based nutrition and lifestyle recommendation
Number of subjects: 62
Study 37674889 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study 37675038 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) monotherapy
Number of subjects: 184
Study 37675038 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release carbamazepine (CBZ-CR) monotherapy
Number of subjects: 184
Study 37675090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin-strut biodegradable polymer sirolimus-eluting stents (BP-SES)
Number of subjects: 360
Study 37675090 — intervention group
Group type: COMPARATOR
Intervention: Thin-strut durable polymer zotarolimus-eluting stents (DP-ZES)
Number of subjects: 360
Study 37675355 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab combined with plasmapheresis
Number of subjects: 0
Study 37675355 — intervention group
Group type: COMPARATOR
Intervention: Plasmapheresis alone
Number of subjects: 0
Study 37675585 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic stiffness measured by carotid to femoral pulse wave velocity (PWV)
Number of subjects: 109
Study 37675585 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline values of PWV, GLS, PWV/GLS ratio and reservoir left atrial strain
Number of subjects: 109
Study 37675585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline values of PWV and less impaired GLS and PWV/GLS
Number of subjects: 109
Study 37675613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg daily for 180 days
Number of subjects: 55
Study 37675613 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care anticoagulation (warfarin or low-molecular-weight heparin) for 180 days
Number of subjects: 55
Study 37675756 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinfection mucosal IgA concentrations
Number of subjects: 0
Study 37675756 — intervention group
Group type: EXPERIMENTAL
Intervention: Postvaccination mucosal IgG concentrations
Number of subjects: 0
Study 37675756 — intervention group
Group type: COMPARATOR
Intervention: ACE2-inhibiting activity
Number of subjects: 0
Study 37675756 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection-induced binding inhibition
Number of subjects: 0
Study 37675756 — intervention group
Group type: EXPERIMENTAL
Intervention: Postvaccination binding inhibition
Number of subjects: 0
Study 37675828 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for recent HCV infection
Number of subjects: 212
Study 37675828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained high probability IDU trajectory
Number of subjects: 212
Study 37675828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained high probability chemsex trajectory
Number of subjects: 212
Study 37675834 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary distribution of HIV self-tests (HIVST)
Number of subjects: 500
Study 37675834 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC; invitation letter to male partner for fast-track testing)
Number of subjects: 500
Study 37675901 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-specific cardiovascular risk factors (CRF) - history of AIDS
Number of subjects: 1243
Study 37675901 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-specific cardiovascular risk factors (CRF) - higher age at diagnosis of HIV infection (per 10 years)
Number of subjects: 1243
Study 37675901 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CD4/CD8 ratio (per standard deviation)
Number of subjects: 1243
Study 37675901 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer cumulative duration of antiretroviral therapies
Number of subjects: 1243
Study 37675901 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of HIV infection (per 10 years)
Number of subjects: 1243
Study 37675901 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking (traditional CRF)
Number of subjects: 1243
Study 37675973 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-IB
Number of subjects: 29
Study 37675973 — intervention group
Group type: COMPARATOR
Intervention: ACL-R
Number of subjects: 29
Study 37676105 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC-PB+ (short corpus callosum with Probst bundles)
Number of subjects: 22
Study 37676105 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC-PB- (short corpus callosum without Probst bundles)
Number of subjects: 22
Study 37676105 — intervention group
Group type: COMPARATOR
Intervention: Normal CC
Number of subjects: 22
Study 37676110 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combined with dose-dense paclitaxel and carboplatin (Apa+ddTCb)
Number of subjects: 25
Study 37676110 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense paclitaxel plus carboplatin (ddTCb)
Number of subjects: 25
Study 37676200 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD (Subcutaneous Implantable Cardioverter-Defibrillator)
Number of subjects: 1637
Study 37676209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical wave imaging in healthy subjects
Number of subjects: 76
Study 37676209 — intervention group
Group type: COMPARATOR
Intervention: Mechanical wave imaging in patients with severe AS
Number of subjects: 76
Study 37676259 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab in combination with durvalumab
Number of subjects: 1171
Study 37676259 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 1171
Study 37676282 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPI)
Number of subjects: 802
Study 37676282 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 802
Study 37676282 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 802
Study 37676612 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg IV/300 mg orally once daily (twice daily on day 1)
Number of subjects: 575
Study 37676612 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole 4 mg/kg IV twice daily/200 mg orally twice daily (6 mg/kg on day 1)
Number of subjects: 575
Study 37676661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive working memory training program (Cogmed software) for 8 weeks (25 sessions)
Number of subjects: 169
Study 37676661 — intervention group
Group type: COMPARATOR
Intervention: Standard management (control)
Number of subjects: 169
Study 37676706 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence based intervention provided by trained young adult volunteers using a digital storytelling platform
Number of subjects: 103
Study 37676706 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 103
Study 37676714 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based self-monitoring intervention
Number of subjects: 199
Study 37676714 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 199
Study 37676715 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise prehabilitation program (details on dosage and duration not available)
Number of subjects: 0
Study 37676715 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise prehabilitation program
Number of subjects: 0
Study 37676720 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized risk communication and screening recommendations via a newly designed brochure
Number of subjects: 880
Study 37676720 — intervention group
Group type: COMPARATOR
Intervention: Usual brochure of the Vaud CRC screening program
Number of subjects: 880
Study 37676727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (8 hours bed rest)
Number of subjects: 34
Study 37676727 — intervention group
Group type: COMPARATOR
Intervention: Control group (24 hours bed rest)
Number of subjects: 34
Study 37676977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 0
Study 37676977 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37677000 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanocortin Pan-Agonist PL9643, dosage and duration not available
Number of subjects: 0
Study 37677000 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37677076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg (LEM10)
Number of subjects: 33
Study 37677076 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 33
Study 37677111 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO systems
Number of subjects: 210
Study 37677111 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology Attitude Scale-Adapted
Number of subjects: 210
Study 37677752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayama
Number of subjects: 60
Study 37677752 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing exercises
Number of subjects: 60
Study 37677752 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 37677894 — intervention group
Group type: EXPERIMENTAL
Intervention: PREMIUM CAT-ACC (computerized adaptive testing tool)
Number of subjects: 496
Study 37677918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort A
Number of subjects: 53
Study 37677918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort B
Number of subjects: 53
Study 37677918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort C
Number of subjects: 53
Study 37677918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab in cohort A
Number of subjects: 53
Study 37677918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab in cohort B
Number of subjects: 53
Study 37677918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab in cohort C
Number of subjects: 53
Study 37677918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Number of subjects: 53
Study 37678215 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation group (n = 29)
Number of subjects: 54
Study 37678215 — intervention group
Group type: COMPARATOR
Intervention: Home-based paper group (n = 28)
Number of subjects: 54
Study 37678222 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine/heparin catheter lock solution (13.5 mg/ml taurolidine and 1000 units/ml heparin)
Number of subjects: 795
Study 37678222 — intervention group
Group type: COMPARATOR
Intervention: Heparin control catheter lock solution (1000 units/ml)
Number of subjects: 795
Study 37678222 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine/heparin catheter lock solution
Number of subjects: 795
Study 37678222 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine/heparin and Heparin
Number of subjects: 795
Study 37678222 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine/heparin
Number of subjects: 795
Study 37678233 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction and relaxation (52 patients)
Number of subjects: 106
Study 37678233 — intervention group
Group type: COMPARATOR
Intervention: 2-dimensional sham presentations (54 patients)
Number of subjects: 106
Study 37678233 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction and relaxation
Number of subjects: 106
Study 37678236 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (300 mg/1.73 m²)
Number of subjects: 41
Study 37678257 — intervention group
Group type: EXPERIMENTAL
Intervention: Calpain inhibitors
Number of subjects: 0
Study 37678257 — intervention group
Group type: EXPERIMENTAL
Intervention: TRPC6 knockdown
Number of subjects: 0
Study 37678257 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic overexpression of calpastatin
Number of subjects: 0
Study 37678257 — intervention group
Group type: COMPARATOR
Intervention: TRPC6 overexpression in podocytes (in human kidney biopsies)
Number of subjects: 0
Study 37678260 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTS
Number of subjects: 569
Study 37678260 — intervention group
Group type: COMPARATOR
Intervention: ICS
Number of subjects: 569
Study 37678274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone sodium tazobactam sodium (CSTS)
Number of subjects: 0
Study 37678274 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (MEPM)
Number of subjects: 0
Study 37678274 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem plus immunoglobulin (MEPM+IVIG)
Number of subjects: 0
Study 37678277 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and capecitabine (DOX regimen)
Number of subjects: 300
Study 37678277 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with oxaliplatin plus capecitabine (XELOX regimen)
Number of subjects: 300
Study 37678277 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 300
Study 37678284 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-IRT system
Number of subjects: 2100
Study 37678342 — intervention group
Group type: EXPERIMENTAL
Intervention: K-wires exposed above the skin by 2 cm (Group I)
Number of subjects: 60
Study 37678342 — intervention group
Group type: COMPARATOR
Intervention: K-wires buried under the skin (Group II)
Number of subjects: 60
Study 37678374 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive message delivered through audio tape (phase 1)
Number of subjects: 251
Study 37678374 — intervention group
Group type: COMPARATOR
Intervention: Standard message delivered through audio tape (phase 1)
Number of subjects: 251
Study 37678374 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive message delivered by nurse (phase 2)
Number of subjects: 251
Study 37678374 — intervention group
Group type: COMPARATOR
Intervention: Standard message delivered by nurse (phase 2)
Number of subjects: 251
Study 37678381 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical cardiac group
Number of subjects: 1100
Study 37678381 — intervention group
Group type: COMPARATOR
Intervention: Surgical cardiac group
Number of subjects: 1100
Study 37678381 — intervention group
Group type: COMPARATOR
Intervention: Noncardiac group
Number of subjects: 1100
Study 37678447 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week group tele-exercise program
Number of subjects: 22
Study 37678574 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-γ ELISpot assay
Number of subjects: 393
Study 37678574 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 393
Study 37678574 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) model
Number of subjects: 393
Study 37678574 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-γ ELISpot incorporated in prediction model
Number of subjects: 393
Study 37678575 — intervention group
Group type: EXPERIMENTAL
Intervention: HLH-related gene variants (LYST, PRF1, UNC13-D, STX11, STXBP2, RAB27A, XIAP, SAP)
Number of subjects: 130
Study 37678575 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 1 variant allele
Number of subjects: 130
Study 37678575 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 2-3 variant alleles
Number of subjects: 130
Study 37678704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 0
Study 37678916 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37678915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 0
Study 37678915 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide-resistant cells
Number of subjects: 0
Study 37678921 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI613 (pharmacological inhibitor)
Number of subjects: 0
Study 37678921 — intervention group
Group type: EXPERIMENTAL
Intervention: shRNA targeting PDHA1 and OGDH
Number of subjects: 0
Study 37678921 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of TCA cycle
Number of subjects: 0
Study 37678943 — intervention group
Group type: EXPERIMENTAL
Intervention: vNOTES
Number of subjects: 100
Study 37678943 — intervention group
Group type: COMPARATOR
Intervention: Conventional Abdominal Laparoscopy (CAL)
Number of subjects: 100
Study 37678946 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroCARE intervention (six individual telehealth sessions over 12 weeks)
Number of subjects: 120
Study 37678946 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 120
Study 37678946 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroCARE intervention
Number of subjects: 120
Study 37679247 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography (CCTA)
Number of subjects: 0
Study 37679247 — intervention group
Group type: COMPARATOR
Intervention: Invasive imaging modalities (IVUS, NIRS-IVUS, OCT)
Number of subjects: 0
Study 37679276 — intervention group
Group type: EXPERIMENTAL
Intervention: gp145 C.6980 high dose (300 mcg), n = 25
Number of subjects: 45
Study 37679276 — intervention group
Group type: EXPERIMENTAL
Intervention: gp145 C.6980 low dose (100 mcg), n = 15
Number of subjects: 45
Study 37679276 — intervention group
Group type: COMPARATOR
Intervention: Placebo/saline, n = 5
Number of subjects: 45
Study 37679276 — intervention group
Group type: EXPERIMENTAL
Intervention: gp145 C.6980 (both doses), n = 40
Number of subjects: 45
Study 37679434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (D) and Quercetin (Q)
Number of subjects: 5
Study 37679536 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal eGFR
Number of subjects: 6720
Study 37679536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild CKD (eGFR=60-89 mL/min/1.73 m²)
Number of subjects: 6720